WaveMan
WaveMan · Company
ATTO · Attovia Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ATTO Attovia Therapeutics (ATTO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0002058707
Quote by TradingView
Cluster · 6 insidersActivist 13DForm 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
14
Codes C/M, not in net · $0 priced

What the filings say about ATTO

Insiders, 180 days
+$47.9M net bought
6 buyers · 2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.2M
1 notice
Activist stakes (13D), 180 days
1 filing
Largest: 13.5% of the class

Attovia Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Attovia Therapeutics, Inc. insiders bought a net $47.9M of stock across 53 Form 4 purchases and sales, with 6 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Frazier Life Sciences XI, L.P.
BUY
2026-08-06 SEC
588,235
$10.0M
-31.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 9.6% of the 6,154,213 shares held after it.
  • 5 other insiders bought within 30 days.
Insider activity: Insider Frazier Life Sciences XI, L.P. bought about $10.0M of ATTO on Aug 6, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days.
Sanofi
BUY
2026-08-07 SECtraded 2026-08-06
300,000
$5.1M
-30.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 27.7% of the 1,082,855 shares held after it.
  • 5 other insiders bought within 30 days.
Insider activity: Insider Sanofi bought about $5.1M of ATTO on Aug 6, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days.
Redmile Group, LLC
BUY
2026-08-07 SECtraded 2026-08-06
200,000
$3.4M
-30.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 20.3% of the 982,854 shares held after it.
  • 5 other insiders bought within 30 days.
Insider activity: Insider Redmile Group, LLC bought about $3.4M of ATTO on Aug 6, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days.
Redmile Group, LLC
BUY
2026-08-07 SECtraded 2026-08-06
400,000
$6.8M
-30.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 33.8% of the 1,182,854 shares held after it.
  • 5 other insiders bought within 30 days.
Insider activity: Insider Redmile Group, LLC bought about $6.8M of ATTO on Aug 6, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days.
venBio Global Strategic Fund IV, L.P.
BUY
2026-08-10 SECtraded 2026-08-06
382,352
$6.5M
-25.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 9.1% of the 4,181,367 shares held after it.
  • 5 other insiders bought within 30 days.
Insider activity: Insider venBio Global Strategic Fund IV, L.P. bought about $6.5M of ATTO on Aug 6, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days.
53 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 48 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$47.9M over 180 days
+$47.9M over 90 days · +$31.8M of it by a 10%+ holder
more than 98% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
-4597.1% net margin (latest quarter)
below 97% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
6.3% of the float short (float per yahoo 2026-10-26) · 3.0 days to cover · settled 2026-09-30
below 56% of Pharma & Biotech
The situation: each line is one rule over one dataset
6 insiders bought a net $47.9M, but 1 Form 144 notice ($2.2M) are queued to sell.
Frazier Life Sciences Public Fund, L.P. disclosed a 5%+ stake (1.7%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ATTO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-36.6%12M
-37%-19%-1%+17%2026-082026-082026-082026-092026-092026-102026-10 2026-08-06 · Frazier Life Sciences XI, L.P. bought $10.0M2026-08-06 · WALSH COLIN bought $8.5M2026-08-06 · GOLDMAN SACHS GROUP INC bought $8.5M2026-08-06 · Redmile Group, LLC bought $6.8M2026-08-06 · venBio Global Strategic Fund IV, L.P. bought $6.5M2026-08-06 · Sanofi bought $5.1M2026-08-06 · Redmile Group, LLC bought $3.4M2026-08-05 · WALSH COLIN bought $1.8M2026-08-05 · GOLDMAN SACHS GROUP INC bought $1.8M2026-08-05 · WALSH COLIN sold $1.6M2026-08-05 · GOLDMAN SACHS GROUP INC sold $1.6M2026-08-05 · WALSH COLIN sold $153.5K2026-08-05 · GOLDMAN SACHS GROUP INC sold $153.5K2026-08-05 · WALSH COLIN sold $146.1K2026-08-05 · GOLDMAN SACHS GROUP INC sold $146.1K2026-08-05 · WALSH COLIN sold $74.9K2026-08-05 · GOLDMAN SACHS GROUP INC sold $74.9K2026-08-05 · WALSH COLIN sold $34.3K2026-08-05 · GOLDMAN SACHS GROUP INC sold $34.3K2026-08-05 · WALSH COLIN sold $29.3K2026-08-05 · GOLDMAN SACHS GROUP INC sold $29.3K2026-08-05 · WALSH COLIN sold $25.8K2026-08-05 · GOLDMAN SACHS GROUP INC sold $25.8K2026-08-05 · WALSH COLIN sold $25.8K2026-08-05 · GOLDMAN SACHS GROUP INC sold $25.8K2026-08-05 · WALSH COLIN sold $22.9K2026-08-05 · GOLDMAN SACHS GROUP INC sold $22.9K2026-08-05 · WALSH COLIN sold $21.8K2026-08-05 · GOLDMAN SACHS GROUP INC sold $21.8K2026-08-05 · WALSH COLIN sold $16.5K2026-08-05 · GOLDMAN SACHS GROUP INC sold $16.5K2026-08-05 · WALSH COLIN sold $15.4K2026-08-05 · GOLDMAN SACHS GROUP INC sold $15.4K2026-08-05 · WALSH COLIN sold $14.8K2026-08-05 · GOLDMAN SACHS GROUP INC sold $14.8K2026-08-05 · WALSH COLIN sold $10.3K2026-08-05 · GOLDMAN SACHS GROUP INC sold $10.3K2026-08-05 · WALSH COLIN sold $9.8K2026-08-05 · GOLDMAN SACHS GROUP INC sold $9.8K2026-08-05 · WALSH COLIN sold $9.6K2026-08-05 · GOLDMAN SACHS GROUP INC sold $9.6K2026-08-05 · WALSH COLIN sold $8.8K2026-08-11 · Frazier Life Sciences Public Fund, L.P. filed a 5%+ stake (1.7%)2026-08-11 · FHMLSP, L.P. filed a 5%+ stake (1.7%)2026-08-11 · FHMLSP, L.L.C. filed a 5%+ stake (1.7%)2026-08-11 · Frazier Life Sciences XI, L.P. filed a 5%+ stake (13.5%)2026-08-11 · FHMLS XI, L.P. filed a 5%+ stake (13.5%)2026-08-11 · FHMLS XI, L.L.C. filed a 5%+ stake (13.5%)2026-08-11 · Frazier Life Sciences XII, L.P. filed a 5%+ stake (0.1%)2026-08-11 · FHMLS XII, L.P. filed a 5%+ stake (0.1%)2026-08-11 · FHMLS XII, L.L.C. filed a 5%+ stake (0.1%)2026-08-28 · GOLDMAN SACHS GROUP INC filed to sell $2.2M
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ATTO: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in ATTO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Frazier Life Sciences Public Fund, L.P.
Activist 13D · 2026-08-11
1.7%
FHMLSP, L.P.
Activist 13D · 2026-08-11
1.7%
FHMLSP, L.L.C.
Activist 13D · 2026-08-11
1.7%
Frazier Life Sciences XI, L.P.
Activist 13D · 2026-08-11
13.5%
FHMLS XI, L.P.
Activist 13D · 2026-08-11
13.5%

ATTO planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
GOLDMAN SACHS GROUP INC
Filed 2026-08-28
$2.2M
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
1 active
1
Phase 2
1 active
What changed recently
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic
2026-09-12 · Completion moved 2026-05 → 2026-06-11
Phase 1
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic
2026-09-12 · Active Not Recruiting → Completed
Phase 1
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic
2026-09-12 · Active Not Recruiting → Completed
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
6 insiders reported buying shares.
The record shows a net $47.9M bought by insiders over 180 days, $2.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ATTO financials

Net margin
-4597.1%

ATTO Stock Sonar score 2/7 axes

Find similar shapesCompare
Insider conviction
98
Inputs
  • Net Form 4 buying (codes P and S), 180d$47.9M · 98 pct, sector of 428
  • Insider buyers, 180d6 · 97 pct, sector of 437
Risk and compliance
53
Inputs
  • Short interest, % of float+6.3% · 53 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ATTO filings, in plain words

Are Attovia Therapeutics insiders buying or selling ATTO?

In the 180 days to 2026-10-27, Attovia Therapeutics insiders were net buyers, a net $47.9M: $52.4M of purchases and $4.5M of sales reported on Form 4, by 6 buyers and 2 sellers.

Are there planned insider sales of ATTO?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $2.2M of stock; the latest, by GOLDMAN SACHS GROUP INC, was filed 2026-08-28.

Read the full summary

In the 180 days to 2026-10-27, Attovia Therapeutics insiders were net buyers of ATTO, a net $47.9M across purchases and sales reported on Form 4 by 6 buyers and 2 sellers. Most of that figure, $31.8M, came from a holder of 10% or more rather than an officer or director. 6 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. None of the 44 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $2.2M of stock. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 13.5% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies